RT Journal Article
SR Electronic
T1 Safety and Effectiveness of LC16m8 for Pre-Exposure Prophylaxis against mpox in a High-Risk Population: An Open-Label Randomized Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.06.24308551
DO 10.1101/2024.06.06.24308551
A1 Okumura, Nobumasa
A1 Morino, Eriko
A1 Nomoto, Hidetoshi
A1 Yanagi, Mashiho
A1 Takahashi, Kozue
A1 Iwasaki, Haruka
A1 Uemura, Yukari
A1 Shimizu, Yosuke
A1 Mizushima, Daisuke
A1 Fukushima, Kazuaki
A1 Kinai, Ei
A1 Shiojiri, Daisuke
A1 Itoda, Ichiro
A1 Onoe, Yasuhiko
A1 Kobori, Yoshitomo
A1 Nakamura, Fukumi
A1 Tokita, Daisuke
A1 Sugiura, Wataru
A1 Ohmagari, Norio
A1 Ujiie, Mugen
YR 2024
UL http://medrxiv.org/content/early/2024/06/07/2024.06.06.24308551.abstract
AB Background The incidence of mpox cases has surged outside endemic regions since May 2022. However, data regarding the safety and efficacy of the LC16m8 vaccine are limited. This study provided opportunities for LC16m8 pre-exposure prophylaxis to high-risk individuals and conducted a randomized controlled trial to assess the effectiveness of LC16m8 in mpox prevention.Methods This multicenter, randomized, open-label trial enrolled men and women aged ≥18 with high mpox risk. Participants were randomly assigned 1:1 to early or late vaccination groups, receiving vaccinations approximately 70 days apart. Vaccine effectiveness (VE) against mpox development between early and late vaccinations was the primary endpoint. VE against severe mpox, symptoms, “take” incidence, and adverse events were secondary endpoints.Results A total of 570 and 565 patients were assigned to the early and late vaccination groups, respectively, and 530 and 476 were vaccinated. The median age was 41 years; 99.7% were male, 89.7% were Japanese, and 34.4% had human immunodeficiency virus (HIV). No mpox cases occurred, precluding VE calculations. The take rate was 90.3% (HIV-infected) and 94.6% (uninfected). Adverse events were observed in 97.2% and 98.2% of patients with and without HIV, respectively. No fatal adverse events were observed. Serious adverse events (SAE) were observed in 0.6% (HIV-infected) and 0.5% (uninfected) of patients. One participant without HIV reported pulmonary embolism and deep vein thrombosis as causally undeniable SAE. Local skin reactions: 96.6% (HIV-infected) and 97.9% (uninfected); systemic reactions: 63.6% (HIV-infected) and 64.2% (uninfected).Conclusions The effectiveness of LC16m8 in mpox remains inconclusive. However, its use in well-controlled HIV-infected and -uninfected individuals showed no significant safety concerns, suggesting the potential for targeted vaccination strategies in at-risk groups. (Japan Registry of Clinical Trials number, jRCT1031230137.)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialJapan Registry of Clinical Trials number, jRCT1031230137.Clinical Protocols https://jrct.niph.go.jp/en-latest-detail/jRCT1031230137 Funding StatementThis study was supported by FY2022 Health, Labour and Welfare Administration Promotion Survey Project Grant (Health, Labour, and Welfare Science Designated Research Project) provided by Ministry of Health, Labour and Welfare [JPMH23HA2019].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study adhered to the principles of the Declaration of Helsinki and the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. This study was approved by the Institutional Review Board of the National Center for Global Health and Medicine (NCGM-S-004692-00).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors